Source comparison
Semax Peptide vs. Selank, N-Acetyl Semax, and Other Analogues: Comparison
Semax peptide is part of a family of synthetic ACTH-derived peptides that includes several structural analogues, each with distinct pharmacological profiles. Understanding these differences is essential for researchers selecting compounds for specific study de
This comparison does not assign a generated winner or score.
- Semax peptide is part of a family of synthetic ACTH-derived peptides that includes several structural analogues, each with distinct pharmacological profiles. Understanding these differences is essential for researchers selecting compounds for specific study designs.
- Semax (standard)
- ACTH(4-10): Met-Glu-His-Phe-Pro-Gly-Pro
- BDNF upregulation, MAO inhibition
- ~70 minutes (intranasal)
- Cognitive enhancement, memory consolidation, neuroprotection after stroke
- The original and most extensively studied variant. Optimal for general cognitive research
- N-Acetyl Semax
- Acetylated N-terminus of Semax
- BDNF upregulation (stronger), extended CNS residence time
- ~4–6 hours
- Long-term neuroplasticity studies, chronic cognitive decline models
- Longer-lasting effects due to acetylation protecting against enzymatic degradation. Best for multi-day protocols
- Semax Amidate
- Amidated C-terminus of Semax
- Similar to standard Semax but higher stability
- ~2–3 hours
- Intranasal cognitive studies where extended activity is needed
- The amide group increases peptide bond stability. Preferred for research requiring consistent dosing
- Selank
- Tuftsin analogue with added proline-glycine-proline tail
- Anxiolytic via GABAergic modulation, immune modulation
- ~30 minutes
- Anxiety models, stress response studies, immune function research
- Structurally related but mechanistically distinct. Primarily anxiolytic rather than nootropic
- The most clinically relevant comparison is between standard Semax peptide and N-Acetyl Semax. The acetyl group added to the N-terminus of N-Acetyl Semax shields the peptide from aminopeptidase cleavage, which is the primary route of degradation for standard Semax peptide. This modification extends the compound's plasma half-life from 70 minutes to approximately 4–6 hours, allowing for once-daily dosing in chronic studies. Research from the Russian Academy of Medical Sciences found that N-Acetyl Semax produced sustained BDNF elevation for 12–16 hours following a single intranasal dose, compared to 6–8 hours for standard Semax peptide. For researchers studying long-term potentiation or chronic neurodegenerative models, N-Acetyl Semax offers a pharmacokinetic advantage.
- Semax Amidate differs from standard Semax peptide by the addition of an amide group at the C-terminus, replacing the free carboxyl group at the terminal proline residue. This modification increases resistance to carboxypeptidase degradation and slightly extends the compound's duration of action to 2–3 hours. Semax Amidate is particularly advantageous for intranasal administration because the nasal mucosa contains high concentrations of peptidases that rapidly cleave unprotected peptide termini. The amide group mitigates this, ensuring more consistent absorption across repeated doses. We stock Semax Amidate Peptide specifically because it offers the best balance of stability and activity for researchers conducting intranasal cognitive protocols.
- Selank, while structurally related, operates through a fundamentally different mechanism. It is derived from the immune peptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro tail, and its primary action is GABAergic modulation rather than BDNF upregulation. Selank reduces anxiety and modulates immune function by influencing interleukin production and serotonin metabolism, but it does not significantly enhance cognitive performance in the same way Semax peptide does. Researchers examining stress-induced cognitive impairment might pair Semax peptide with Selank Amidate Peptide to separate anxiolytic effects from direct nootropic mechanisms.